| An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months. | |
| | |
MedLine Citation:
|
PMID: 21329635 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Aims: Erythropoiesis-stimulating agents (ESAs) are recommended for managing renal anemia. ALTERNATE is an observational study in European and Australian dialysis patients evaluating darbepoetin a (DA) once every 2 weeks (Q2W) in clinical practice. Methods: Adult dialysis patients initiating treatment with DA Q2W were eligible regardless of previous/current ESA use. Data were collected 6 months before and 12 months after Q2W initiation. The primary endpoint was hemoglobin (Hb) concentration 12 months after initiation. Results:>/u> A total of 6,112 patients were enrolled; 6,104 were eligible (87% hemodialysis, 12% peritoneal dialysis). Before initiation, 77.3%, 8.8%, and 7.8% of patients were receiving DA, epoetin beta, and epoetin alpha, respectively; 6% were ESA naïve. Mean (95% CI) Hb (g/dl) was 11.68 (11.63 - 11.72) 6 months before initiation, 12.00 (11.97 - 12.04) at initiation, and 11.62 (11.58 - 11.66) 12 months after initiation. Geometric mean (95% CI) weekly ESA dose (µg/wk) was 27.27 (26.62 - 27.93) immediately before initiation, 23.69 (23.28 - 24.10) at initiation, and 26.80 (26.12 - 27.49) 12 months after initiation. At month 12, 77.3% of patients were receiving DA Q2W. Conclusions: This large observational study demonstrates that Hb concentrations can be effectively maintained over 12 months in a general dialysis population with DA Q2W without an increase in ESA dose. |
| | |
Authors:
|
J B Rottembourg; I Bridges; W Pronai; M Feriani; L P McMahon; J M J De Meester; M Farouk; B Molemans |
Related Documents
:
|
20502745 - Coblation® inferior turbinate reduction: a long-term follow-up with subjective and obj... 18585555 - Evidence supporting functional rhinoplasty or nasal valve repair: a 25-year systematic ... 1544695 - Treatment of idiopathic oligozoospermia with tamoxifen--a randomized controlled study. 21333545 - Early and delayed stroke after coronary surgery - an analysis of risk factors and the i... 11996255 - Endovascular treatment of thoracic disease: patient selection and a proposal of a risk ... 17423045 - Comparison of penicillin, oxytetracycline, and trimethoprim-sulfadoxine in the treatmen... |
Publication Detail:
|
Type: JOURNAL ARTICLE |
Journal Detail:
|
Title: Clinical nephrology Volume: 75 ISSN: 0301-0430 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-2-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0364441 Medline TA: Clin Nephrol Country: - |
Other Details:
|
Languages: ENG Pagination: 242-250 Citation Subset: - |
Affiliation:
|
1Centre Suzanne Levy, Diaverum Group, Clinique du Mont Louis, Paris, France, 2Amgen Ltd., Cambridge, UK, 3Barmherzige Brüder Eisenstadt, Eisenstadt, Austria, 4Ospedale dell'Angelo, Via Pacagnella, Mestre, Italy, 5Eastern Health, Melbourne, Australia, 6AZ Nikolaas, Sint-Niklaas, Belgium, and 7Amgen (Europe) GmbH, Zug, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy...
Next Document: Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based co...